Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
BGSF BGSF Inc
NEE Nextera Energy Inc
PSB-Y PS Business Parks Inc
ADBE Adobe Inc
APWL Advanced Powerline Technologies Inc
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Closing Price
$13.07
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
421,045
0

RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drug

8:48 am ET October 4, 2021 (MarketWatch)
Print

Shares of Redhill Biopharma Ltd. (RDHL) gained 7.0% in premarket trading on Monday after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized COVID-19 patients. Redhill said the treatment candidate reduced mortality by 62% when evaluating 251 of the 475 patients enrolled in the study. Several companies developing COVID-19 drugs have shared new data since Friday, when Merck & Co. Inc. (MRK) said its experimental oral COVID-19 treatment helped keep people out of the hospital and from dying. The news sent Merck's shares soaring and created widespread excitement among clinicians. RedHill's stock is down 45.9% for the year, while the broader S&P 500 [S: spx] is up 14.7%.

-Jaimy Lee

	

(END) Dow Jones Newswires

October 04, 2021 08:48 ET (12:48 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.